Objective　To explore the clinical significance of determining the levels of plasma TXB2,PAgT,6-Keto-PGF1α in the lung carcinoma patients.Methods　The levels of plasma TXB2,PAgT and 6-Keto-PGF1α were determined in 43 patients with lung carcinoma and 45 healthy controls,and 36 cases of 43 patients with lung carcinoma were randomly divided into two groups:(A) conventional treatment plus warfarin sodium,(B) conventional treatment without anticoagulant.We also determined the level of plasma Fib in both group A and group B,besides examined the levels of plasma TXB2,PAgT and 6-Keto-PGF1α before and after treatment.Results　Statistical analysis showed that the levels of TXB2 and PAgT were significantly higher,but the levels of 6-Keto-PGF1α was significantly lower in the patients with lung carcinoma than those in healthy controls(P＜0.05～0.01).The levels of TXB2,PAgT and Fib in group A were significantly lower,but the level of 6-Keto-PGF1α was significantly higher in group A after treatment than before treatment(P＜0.05～0.01).While these four indexes in group B did not significantly change(P＞0.05).Conclusion　The determination of plasma TXB2,PAgT and 6-Keto-PGF1α for lung carcinoma patients are helpful in diagnosis and treatment of lung carcinoma.

Objective To explore the clinical significance of determining the levels of plasma TXB 2,PAgT,6-Keto-PGF 1? in the lung carcinoma patients.Methods The levels of plasma TXB 2,PAgT and 6-Keto-PGF 1? were determined in 43 patients with lung carcinoma and 45 healthy controls,and 36 cases of 43 patients with lung carcinoma were randomly divided into two groups:(A) conventional treatment plus warfarin sodium,(B) conventional treatment without anticoagulant.We also determined the level of plasma Fib in both group A and group B,besides examined the levels of plasma TXB 2,PAgT and 6-Keto-PGF 1? before and after treatment.Results Statistical analysis showed that the levels of TXB 2 and PAgT were significantly higher,but the levels of 6-Keto-PGF 1? was significantly lower in the patients with lung carcinoma than those in healthy controls(P0 05).Conclusion The determination of plasma TXB 2,PAgT and 6-Keto-PGF 1? for lung carcinoma patients are helpful in diagnosis and treatment of lung carcinoma.

Objective To assess the application value of NCE-MRA using iMSDE prepared bSSFP sequence in lower limb in patients with diabetes. Methods This prospective study included a total of 35 patients with type II diabetes who underwent CE-MRA on the 1.5T MR scanner after the NCE-MRA. The obtained MIP images were independently rated by two radiologist with a four score table and using CE-MRA as a reference standard to evaluate the diagnostic accuracy of NCE-MRA for the narrowed arteries. The difference of the percent age of diagnostic arterial segments between NCE-MRA and CE-MRA on diabetic patients was evaluated by the χ2 test. Results Compared with CE-MRA, the diagnostic-value arterial segment ratio of pelvic arteries on NCE-MRA is decreased significantly. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of two readers in NCE-MRA were 95%/87%, 96%/95%, 57%/72%, 99%/99%, and 96%/95%(k=0.76), respectively. Conclusions The NCE-MRA using iMSDE prepared bSSFP sequence is capable of depicting vascu-lar lesions for the lower extremities in diabetic patients with the advantages of contrast agent free, short scan times and good diagnostic value in the thigh and calves.

To evaluate the safety and effectiveness of Shenbei Guchang capsules in treatment of diarrhea type irritable bowel syndrome (yang deficiency of spleen and kidney) under widely used conditions, an open, multicenter, controlled, phase Ⅳ clinical trial was conducted in the drug clinical trial centers of 16 domestic hospitals. 2 123 patients from June 10, 2011 to November 29, 2012 were enrolled in the trial. Drug clinical trial was approved by Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital Ethics Committee before implementation. Before the start of trial, subjects were selected according to the research scheme and inclusion criteria, then they would step into the 14 d study after signing Informed Consent Form. All subjects were treated according to the research scheme, evaluated the conditions and filled in CFR sheet, to provide the evaluation data and information on safety and efficacy of Shenbei Guchang capsules. Shenbei Guchang capsules were used to treat diarrhea type irritable bowel syndrome in widely used conditions (2 123 cases), and 2 029 cases of them entered FAS set, cure+markedly effective in 1 921 cases, with a comprehensive curative effect rate of 94.68%; 2 010 cases of them entered PPS set, cure+markedly effective in 1 906 cases, with a comprehensive curative effect rate of 94.83%. The primary symptoms of IBS were abdominal pain and diarrhea. After treatment, both abdominal pain and diarrhea were improved, with significant differences (P<0.000 1). There were significant differences in traditional Chinese medicine symptom scores on both post-treatment day 7 and day 14 as compared with the conditions before treatment (P<0.000 1). 35 cases of adverse events occurred during the trial with an incidence of 1.65%, including 12 cases of drug-related adverse events (adverse reaction) with an incidence of 0.57%, mainly manifested as nausea, abdominal distension and dry mouth, most of which would be spontaneously relieved without any measures. No serious adverse events occurred. The commercially available Shenbei Guchang capsules are proved safe and effective for the treatment of diarrhea type irritable bowel syndrome (yang deficiency of spleen and kidney) under widely used conditions (2 123 cases), and can be continued for clinical promotion and application.